To take neratinib/neratinib or not: A key choice in treating HER2-positive breast cancer

Neratinib/Neratinib, usually referred to as neratinib maleate tablets, is an important treatment drug for HER2-positive breast cancer. As a dual tyrosine kinase inhibitor, neratinib can precisely act on the HER2 receptor in the human body and effectively curb the proliferation and spread of breast cancer cells by blocking the HER2 signaling pathway.

For adult patients with HER2-positive early breast cancer, after receiving trastuzumab-containing adjuvant therapy, taking neratinib regularly as directed by the doctor can usually significantly inhibit the growth of HER2-overexpressing tumor cells, thereby more effectively controlling the disease, reducing the risk of tumor recurrence and metastasis, and significantly improving the patient's quality of life. However, if patients choose not to take neratinib, they may not be able to adequately control the progression of the disease, thereby increasing the difficulty of treatment and the risk of recurrence.

However, it is worth noting that neratinib is not suitable for all types of breast cancer. Breast cancer is highly heterogeneous, and different types and stages of breast cancer require different treatment strategies. Neratinib is mainly targeted at patients with HER2-positive breast cancer, especially those who have relapsed after surgery, radiotherapy and trastuzumab. For other types of breast cancer, neratinib may not work as well as expected.

In addition, taking neratinib may also be associated with some adverse reactions, such as diarrhea, nausea, vomiting, and rash. These reactions are common side effects of medications and are controllable in most cases. However, if symptoms continue to worsen, patients should seek medical treatment promptly and follow the doctor's advice to adjust the treatment plan. In particular, patients who are allergic to any component of neratinib, as well as pregnant and lactating women, should consult a professional physician and carefully assess the risks before use.